Japan, Feb. 12 -- RESOLVE THERAPEUTICS LLC has got intellectual property rights for 'OPTIMIZED DOUBLE NUCLEASE FUSION OBJECT AND METHOD.' Other related details are as follows:
Application Number: JP,2022-122570
Category (FI): A61K38/46,A61P19/02,A61P25/00,A61P29/00,A61P3/10,A61P37/02,A61P7/06,C07K19/00,C12N1/15,C12N1/19,C12N1/21,C12N15/13,C12N15/55,C12N15/62@Z,C12N15/63@Z,C12N5/10,C12N9/16@Z,C12N9/22,C12P21/02@C
Stage: Grant (IP right granted following substantive examination.)
Filing Date: Aug. 1, 2022
Publication Date: Oct. 12, 2022
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication....